Search results for "Drug administration"

showing 10 items of 393 documents

The global distribution of lymphatic filariasis, 2000–18:a geospatial analysis

2020

Background Lymphatic filariasis is a neglected tropical disease that can cause permanent disability through disruption of the lymphatic system. This disease is caused by parasitic filarial worms that are transmitted by mosquitos. Mass drug administration (MDA) of antihelmintics is recommended by WHO to eliminate lymphatic filariasis as a public health problem. This study aims to produce the first geospatial estimates of the global prevalence of lymphatic filariasis infection over time, to quantify progress towards elimination, and to identify geographical variation in distribution of infection. Methods A global dataset of georeferenced surveyed locations was used to model annual 2000–18 lym…

medicine.medical_specialtyGeospatial analysis030231 tropical medicineElephantiasis:ELIMINATIONcomputer.software_genreArticleLocal Burden of Disease 2019 Neglected Tropical Diseases Collaborators1117 Public Health and Health Services03 medical and health sciences0302 clinical medicineRA0421Environmental healthGlobal healthmedicine030212 general & internal medicineMass drug administrationLymphatic filariasisPublic healthlcsh:Public aspects of medicineTropical diseaselcsh:RA1-1270General Medicinemedicine.disease3. Good healthQRGeographyLymphatic systemITC-ISI-JOURNAL-ARTICLEA990 Medicine and Dentistry not elsewhere classifiedITC-GOLDcomputer0605 Microbiology
researchProduct

Non-Hemodynamic Effects of Organic Nitrates and the Distinctive Characteristics of Pentaerithrityl Tetranitrate

2009

Organic nitrates are among the oldest and yet most commonly employed drugs in the long-term therapy of coronary artery disease and congestive heart failure. While they have long been used in clinical practice, our understanding of their mechanism of action and side effects remains incomplete. For instance, recent findings provide evidence of previously unanticipated, non-hemodynamic properties that include potentially beneficial mechanisms (such as the induction of a protective phenotype that mimics ischemic preconditioning), but also toxic effects (such as endothelial and autonomic dysfunction, rebound angina, tolerance). To date, the most commonly employed organic nitrates are isosorbide …

medicine.medical_specialtyHeart DiseasesVasodilator AgentsIsosorbide DinitratePharmacologyDrug Administration ScheduleAnginaCoronary artery diseaseNitroglycerinmedicineIsosorbide mononitrateAnimalsHumansPentaerythritol TetranitratePharmacology (medical)NitroglycerinNitratesbusiness.industryDrug ToleranceGeneral Medicinemedicine.diseaseSurgeryEastern europeanOxidative StressHeart failureIschemic preconditioningIsosorbide dinitrateReactive Oxygen SpeciesCardiology and Cardiovascular Medicinebusinessmedicine.drugAmerican Journal of Cardiovascular Drugs
researchProduct

Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review

2011

In this paper we describe the results of a systematic search of the literature on conversion ratios during opioid switching. This is part of a project of the European Palliative Care Research Collaboration to update the European Association for Palliative Care recommendations for the use of opioid analgesics in the treatment of cancer pain. Studies were eligible for inclusion if they involved adult patients with chronic cancer pain, contained data on opioid conversion ratios, were prospective and were written in English. Thirty-one studies were identified and included. The majority of the studies had methodological flaws and were not designed to explore or demonstrate equianalgesic dose da…

medicine.medical_specialtyPalliative careMEDLINEPainDrug Administration ScheduleFentanylNeoplasmsmedicineHumansDrug Dosage CalculationsDosingIntensive care medicinePain MeasurementRandomized Controlled Trials as TopicDose-Response Relationship Drugbusiness.industryGeneral MedicineEquianalgesicAnalgesics OpioidEuropeAnesthesiology and Pain MedicineOpioidAnesthesiaPractice Guidelines as TopicCancer painbusinessmedicine.drugBuprenorphinePalliative Medicine
researchProduct

Combined 5-fluorouracil and recombinant alpha-2a-interferon vs. 5-fluorouracil alone in metastatic colorectal carcinoma: a multicenter randomized stu…

1991

medicine.medical_specialtyPathologyColorectal cancermedicine.medical_treatmentInterferon alpha-2GastroenterologyDrug Administration ScheduleMetastasisInterferonInternal medicinemedicineCarcinomaHumansChemotherapyEpitheliomabusiness.industryInterferon-alphaGeneral MedicineImmunotherapymedicine.diseaseCombined Modality TherapyRecombinant ProteinsOncologyFluorouracilColonic NeoplasmsSurgeryFluorouracilbusinessmedicine.drugJournal of surgical oncology. Supplement
researchProduct

Confocal Laser Endomicroscopy: Technical Advances and Clinical Applications

2010

Since its introduction in 2004, confocal laser endomicroscopy (CLE) has emerged as a valuable tool for gastrointestinal endoscopic imaging. Endomicroscopy enables the endoscopist to obtain real time in vivo histology during ongoing endoscopy thereby creating “optical biopsies.” To date, numerous studies have shown potential applications of endomicroscopy in the clinical setting, including in vivo diagnosis of esophageal squamous cell carcinoma, Barrett’s esophagus, celiac disease, and colonic polyps. Moreover, recent data suggest the potential application of endomicroscopy in the field of molecular imaging. Additionally, in recent months new applications and developments in the field of con…

medicine.medical_specialtyPathologyGastrointestinal DiseasesEndoscopy GastrointestinalFood and drug administrationEndoscopic imagingConfocal imagingPredictive Value of TestsmedicineEndomicroscopyHumansConfocal laser endomicroscopyMicroscopy ConfocalMucous MembraneHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyEquipment DesignWide fieldMolecular ImagingEndoscopyEndoscopes GastrointestinalGastrointestinal TractRadiologyMolecular imagingbusinessGastroenterology
researchProduct

Effects of Morning Versus Evening Statin Administration on Lipid Profile: A Systematic Review and Meta-Analysis

2017

Background Evidence about the optimal time of day at which to administer statins is lacking. Objective The objective of this study is to synthesize evidence about effects of morning vs evening statin administration on lipid profile. Methods We searched PubMed, SCOPUS, Web of Science, and Embase databases (from inception up to July 24, 2016) to identify the relevant studies. Mean differences (MDs) between the change scores in lipid parameters were pooled using a fixed-effect model. Results Eleven articles with 1034 participants were eligible for the analysis. The pooled analysis comparing effects of morning vs evening administration of statins on plasma total cholesterol (TC; P  = .10), high…

medicine.medical_specialtyRMEveningStatinmedicine.drug_classEndocrinology Diabetes and MetabolismSubgroup analysis030204 cardiovascular system & hematologyDrug Administration Schedule03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineInternal MedicinemedicineHumans030212 general & internal medicineMorningNutrition and Dieteticsmedicine.diagnostic_testCholesterolbusiness.industryLipidsEndocrinologyPooled analysischemistryMeta-analysislipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicineLipid profilebusiness
researchProduct

Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis

2020

AbstractObjectiveThe randomized, controlled MAINRITSAN2 trial was designed to compare the capacity of an individually tailored therapy [randomization day 0 (D0)], with reinfusion only when CD19+ lymphocytes or ANCA had reappeared, or if the latter’s titre rose markedly, with that of five fixed-schedule 500-mg rituximab infusions [D0 + D14, then months (M) 6, 12 and 18] to maintain ANCA-associated vasculitis (AAV) remissions. Relapse rates did not differ at M28. This ancillary study was undertaken to evaluate the effect of omitting the D14 rituximab infusion on AAV relapse rates at M12.MethodsMAINRITSAN2 trial data were subjected to post-hoc analyses of M3, M6, M9 and M12 relapse-free surviv…

medicine.medical_specialtyRandomizationAntigens CD19Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGastroenterologyDisease-Free SurvivalDrug Administration ScheduleAntibodies Antineutrophil CytoplasmicMaintenance Chemotherapylaw.invention03 medical and health sciences0302 clinical medicineRheumatologyMaintenance therapyRandomized controlled triallawInternal medicinePost-hoc analysismedicineHumansPharmacology (medical)030212 general & internal medicineSurvival rate030203 arthritis & rheumatologybusiness.industrymedicine.diseaseAntirheumatic AgentsRituximabRituximabMicroscopic polyangiitisGranulomatosis with polyangiitisbusinessmedicine.drugRheumatology
researchProduct

US Food and Drug Administration's Risk Evaluation and Mitigation Strategy for Extended-Release and Long-Acting Opioids Pros and Cons, and a European …

2012

Prescriptions for opioid analgesics to manage moderate-to-severe chronic non-cancer pain have increased markedly over the last decade. An unintentional consequence of greater prescription opioid utilization has been the parallel increase in misuse, abuse and overdose, which are serious risks associated with all opioid analgesics. In response to disturbing rises in prescription opioid abuse, the US Food and Drug Administration (FDA) has proposed the implementation of aggressive Risk Evaluation and Mitigation Strategies (REMS). While REMS could dramatically change the development, release, marketing and prescription of extended-release opioids, questions remain on how these programmes may inf…

medicine.medical_specialtyTime FactorsSettore MED/41 - AnestesiologiaLong-Acting Opioids Food and drug administration AnalgesiaRisk AssessmentFood and drug administrationPatient safetyPharmacotherapymedicineHumansPharmacology (medical)Medical prescriptionIntensive care medicineUnited States Food and Drug Administrationbusiness.industryPerspective (graphical)Chronic painLong-Acting Opioids Food and drug administration AnalgesiaOpioid-Related Disordersmedicine.diseaseUnited StatesRisk evaluationAnalgesics OpioidEuropeDelayed-Action PreparationsMedical emergencyChronic PainRisk assessmentbusiness
researchProduct

How should we determine length of anticoagulation after proximal deep vein thrombosis of the lower limbs?

2009

The current approach for deciding the duration of vitamin K antagonist (VKA) treatment after an episode of venous thrombo-embolism (VTE) is mainly based on the characteristic of the index event (3 months or longer in case of unknown/persistent risk factors, 3 months or less in case of removable causes). However, the length of anticoagulation should be tailored on the patient's risk for recurrent thrombosis as well as for bleeding, but such 'time for decision' is often unclear and the optimal duration of VKA remains debatable. The presence of persistent residual vein thrombosis and increased D-dimer levels after stopping therapy are predictors for recurrent deep vein thrombosis (DVT). Manage…

medicine.medical_specialtyTime FactorsVitamin Kmedicine.drug_classDeep veinRisk AssessmentDrug Administration ScheduleRecurrent deep vein thrombosisSettore MED/15 - Malattie Del SangueFibrin Fibrinogen Degradation ProductsFibrinolytic AgentsRecurrenceNeoplasmsmedicineHumansVenous ThrombosisFirst episodebusiness.industryVascular diseaseAnticoagulantVitaminsHematologyVitamin K antagonistmedicine.diseaseThrombosisduration anticoagulants venous thromboembolismSurgeryVenous thrombosismedicine.anatomical_structurebusinessBiomarkersBritish Journal of Haematology
researchProduct

Evaluation of low-dose metronomic (LDM) cyclophosphamide toxicity in cats with malignant neoplasia

2014

Oral administration of low-dose cyclophosphamide in pets with spontaneously occurring malignant neoplasms has become a common practice in veterinary medicine. The purpose of this retrospective study was to investigate toxicity events in cats with spontaneous malignancies receiving cyclophosphamide as a metronomic therapy for at least 1 month. The number and severity of clinical, haematological and biochemical adverse events were recorded according to the Veterinary Cooperative Oncology Group’s Common Terminology Criteria for Adverse Events v1.1 classification scheme. Twenty-four cats were enrolled in the study with a total number of 27 neoplasms: 13 sarcomas, 12 carcinomas, one melanoma an…

medicine.medical_specialtyToceranibCyclophosphamideCat DiseasesGastroenterologyDisease-Free SurvivalDrug Administration ScheduleMetastasisNeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsSmall AnimalsAdverse effectAntineoplastic Agents AlkylatingCyclophosphamideNeoplasm StagingRetrospective StudiesCATSDose-Response Relationship Drugbusiness.industryCommon Terminology Criteria for Adverse Eventsmedicine.diseaseSurgeryThalidomideToxicityCatsbusinessmedicine.drugJournal of Feline Medicine and Surgery
researchProduct